| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.5315125 |
| In contrast , in agreement with a recent work ( Kornblatt et al . , Biochem Biophys Res Commun 2003 ; 305 : 518 ) , in this paper we present a detailed thermodynamic and kinetic characterization of the interaction between recombinant bovine PrP ( c 25 242 ) and the human serum component plasminogen , measured using a resonant mirror technique : our results reveal a high affinity interaction between the two binding partners . 0.5315125^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :1.3994828 |
| Plasminogen , a serine protease precursor , has been shown to interact with PrP ( Sc ) . 1.3994828^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.58033238 |
| The presence of C 1 fragment in homogenates from plasminogen deficient mice in a comparable ratio with full length PrP as can be found in wild type animals indicates that other proteases in addition to plasmin are responsible for PrP cleavage in vivo . . 0.58033238^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| Thus , the inhibition in PRP depended on generation of FDPs by activated plasminogen . ^^^ These observations reconcile disparate results in the literature from studies in vivo and in vitro by demonstrating that inhibition of aggregation of platelets in PRP and in whole blood reflects indirect effects of plasminogen activation rather than direct effects of t PA or plasmin on the platelets themselves . . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| Retinas subjected to PRP or intravenous iodoacetate ( at three weeks or four months ) stimulated migration and proliferation above baseline levels twice as much as control retinas and stimulated plasminogen activator production by twofold to 2 . 5 fold . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| The effects of tissue type plasminogen activator ( t PA ) on the platelet aggregation were studied using citrated whole blood and platelet rich plasma ( PRP ) obtained from human donors . t PA suppressed adenosine 5 ' diphosphate ( ADP ) or collagen induced platelet aggregation in a dose dependent manner . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| Platelet rich plasma ( PRP ) or washed platelets were incubated with the fibrinolytic agents urokinase , recombinant tissue type plasminogen activator ( rt PA ) , or plasmin at concentrations consistent with those in the plasma of patients treated for myocardial infarction . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| Furthermore , two unrelated platelet inhibitors , iloprost and tissue type plasminogen inhibitor , decrease platelet aggregation to a greater extent in whole blood than in PRP . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| Concentrations of fibrinopeptide A , a marker of thrombin activity , increased markedly over 10 minutes in plasma incubated with streptokinase or plasmin , but not in PRP incubated without plasminogen activator . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| Tissue plasminogen activator ( t PA ) and its inhibitor ( PAI ) were assessed in venous blood drawn before and after venous occlusion ( bvo , avo ) for 33 patients with Raynaud ' s phenomenon ( RP ) , 14 with primary RP ( PRP ) , 9 with suspected secondary RP ( SSRP ) , and 10 with definite collagen disease and secondary RP ( SRP ) . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| Using platelet rich plasma ( PRP ) , we found that SK ( 5 , 000 units / ml ) but not urokinase ( 2 , 500 units / ml ) or recombinant tissue type plasminogen activator ( 2 , 500 units / ml ) caused platelet aggregation in PRP from 14 of 100 normal volunteers . ^^^ Addition of SK ( 1 , 000 or 5 , 000 units / ml ) induce a statistically significant dose dependent thromboxane B 2 release in mixtures of PRP with plasma from subjects with SK induced aggregation but not in samples of PRP mixed with plasma from nonresponders ; addition of recombinant tissue type plasminogen activator ( 1 or 50 micrograms / ml ) did not induce thromboxane B 2 release . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| We identify plasminogen , a pro protease implicated in neuronal excitotoxicity , as a PrP ( Sc ) binding protein . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| Our data indicate that platelets activated in platelet rich plasma ( PRP ) by adenosine 5 ' diphosphate ( ADP ) or thrombin bind plasminogen to their surface . ^^^ Platelet aggregation and plasminogen and fibrinogen binding are also concurrently inhibited by the Gly Arg Asp ( RGD ) analogue Gly Arg Gly Asp Ser ( GRGDS ) when it is added to PRP before ADP stimulation . ^^^ Finally , we found both plasminogen and fibrinogen on resting platelets in PRP and demonstrated that they are equally displaced by EDTA , LJ CP 8 , and 10E5 ( an additional anti GPIIb / IIIa monoclonal antibody ) . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| The content of tissue plasminogen activator inhibitor ( t PA 1 ) , and of specific pregnancy plasma PA 1 reacting with antibodies to placental PA 1 , was measured in platelet poor plasma ( PPP ) , platelet rich plasma ( PRP ) , serum and platelet lysate , both from pregnant women and healthy non pregnant ( male or female ) controls . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| To examine the basis of enhanced thrombolytic effect of tissue type plasminogen activator ( t PA ) in the presence of lys or glu plasminogen , studies were performed with human platelet rich plasma ( PRP ) and washed platelets ( WP ) . t PA inhibited platelet aggregation in PRP and this effect was potentiated by lys plasminogen as well as glu plasminogen . t PA inhibited WP aggregation only in the presence of lys or glu plasminogen . ^^^ Anti aggregatory effects of plasmin and lys plasminogen plus t PA on platelets were attenuated by preincubation of PRP or WP suspension with aprotinin . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| METHODS : Under carefully controlled conditions , fasting blood was drawn from 19 healthy control subjects , 10 patients with PRP , 17 with lcSSc and nine with dSSc for measurement of the following : von Willebrand factor ( VWF ) and soluble thrombomodulin as markers of endothelial damage / activation , thromboxane ( as thromboxane B 2 ) and beta thromboglobulin as markers of platelet activation , and tissue plasminogen activator antigen , tissue plasminogen activator activity and plasminogen activator inhibitor 1 ( PAI 1 ) as markers of fibrinolysis . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| Apart from the dimeric form , the molecular weight of salmon PRP and its appearance on SDS PAGE is similar to human plasminogen . ^^^ In addition , cross reactivity between antibodies to human plasminogen and salmon PRP was demonstrated . ^^^ Whether salmon PRP is a new type of phosphorylcholine binding protein with an unknown function or a plasminogen like protein with binding specificity for phosphorylcholine calls for further investigation . . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| Discrimination between these isoforms would significantly enhance diagnosis of these diseases , and it has recently been reported that PrP ( Sc ) is specifically recognized by the serine protease zymogen plasminogen ( Fischer et al . ( 2000 ) Nature 408 , 479 ) . ^^^ Here we have tested the hypothesis that PrP is a regulator of the plasminogen activation system . ^^^ The effect of recombinant PrP , either containing copper ( holo PrP ) or devoid of it ( apo PrP ) , on plasminogen activation by both uPA and tPA was determined . ^^^ PrP had no effect on plasminogen activation by uPA . ^^^ The copper binding octapeptide repeat region of PrP was involved in the effects , as a mutant lacking this region failed to stimulate plasminogen activation , although a synthetic peptide corresponding to this region was unable to stimulate tPA activity . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| It was recently published that , as opposed to PrP ( C ) , PrP ( Sc ) , as well as its protease resistant core PrP 27 30 , can bind specifically to plasminogen and other serum components . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| However , proteinase K digestion and plasminogen binding assay of brain homogenates incubated with PDI suggest that PDI has no effect on either proteinase resistance or conformational change of PrP . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| Stimulation of plasminogen activation by recombinant cellular prion protein is conserved in the NH 2 terminal fragment PrP 23 110 . ^^^ The cellular prion protein ( PrP ( c ) ) , tissue type plasminogen activator ( t PA ) and plasminogen are expressed in synaptic membranes in vivo . ^^^ Recently binding of the disease associated isoform of the prion protein ( PrP ( Sc ) ) to plasminogen and stimulation of t PA activity have been reported . ^^^ In this study the interaction of PrP ( c ) and plasminogen was investigated using chromogenic assays in vitro . ^^^ Our results show that the NH ( 2 ) terminal part of PrP ( c ) spanning amino acids 23 110 ( PrP 23 110 ) together with low molecular weight heparin stimulates t PA mediated plasminogen activation in vitro . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| The cellular prion protein ( PrP ( c ) ) forms complexes with plasminogen . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| PO : persistent occlusion CR : cyclic reflow PP : persistent patency PAI 1 : type 1 plasminogen activator inhibitor tPA : tissue type plasminogen activator PBS : phosphate buffer solution IC ( 50 ) : 50 % of inhibitory concentration PRP : platelet rich plasma ADP : adenosine diphosphate AA : arachidonic acid PAF : platelet activating factor . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| Therefore , we compared plasminogen concentrations and plasminogen activities in patients with sporadic CJD and controls with other dementia , which were collected in the framework of the German CJD Surveillance study . ^^^ Patients with CJD had significantly higher plasminogen concentrations than patients with other forms of dementia and plasminogen specific activities were lower in CJD patients . ^^^ The results may reflect a disease specific prion protein and plasminogen interaction in patients with CJD . ^^^ Other possible explanations are plasminogen polymorphisms and genotypes with distinct plasminogen activity levels in CJD than in controls , which should be a subject for further studies . . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| Both lysine clusters of the NH 2 terminal prion protein fragment PrP 23 110 are essential for t PA mediated plasminogen activation . ^^^ We have recently shown that the NH ( 2 ) terminal fragment ( PrP 23 110 ) of the human cellular prion protein ( PrP ( c ) ) stimulates t PA mediated plasminogen activation . ^^^ We further studied the binding of soluble PrP 23 110 to immobilized t PA or plasminogen using surface plasmon resonance . ^^^ Binding of t PA or plasminogen to PrP 23 110 was no longer influenced by glycosaminoglycans when PrP 23 110 was immobilized on the chip surface . ^^^ Thus a possible role of heparin as a cofactor in the stimulation of plasminogen activation by t PA could be the generation of a PrP 23 110 form with both lysine clusters accessible for binding of t PA and plasminogen . . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| Recombinant human prion protein ( PrP 23 231 ) stimulates plasminogen activation by tissue type plasminogen activator ( t PA ) . ^^^ It has further been shown by others that PrP ( c ) binds to kringle domains of plasminogen . ^^^ We compared the stimulatory activity of recombinant PrP 23 231 and PrP 23 110 on plasminogen activation catalyzed by t PA , urokinase ( u PA ) , streptokinase and Desmodus salivary plasminogen activator ( DSPAalpha 1 ) . ^^^ As these plasminogen activators are distinct , with respect to their kringle domains we studied their binding to immobilized PrP 23 110 . ^^^ We found that recombinant full length prion protein , PrP 23 231 , and PrP 23 110 specifically stimulate t PA mediated plasminogen activation . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| To investigate whether plasminogen may feature in scrapie infection , we inoculated plasminogen deficient ( Plg ( / ) ) , heterozygous plasminogen deficient ( Plg ( + / ) ) , and wild type ( Plg ( + / + ) ) mice by the intracerebral or intraperitoneal ( i . p . ) route with the RML scrapie strain and monitored the onset of neurological signs of disease , survival time , brain , and accumulation of scrapie disease associated forms of the prion protein ( PrP ( Sc ) ) . ^^^ At the onset of symptoms , PrP ( Sc ) accumulation was higher in the brain and spleen of Plg ( + / + ) and Plg ( + / ) mice than in those of Plg ( / ) mice , and these differences were paralleled by differences in the severity of spongiform changes and astrogliosis in the cerebral cortex and subcortical gray structures . ^^^ |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P00747 and P04156 |
Pubmed |
SVM Score :0.0 |
| NA |
|